Roche receives FDA approval for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY | News

Roche receives FDA approval for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY | News

The new VENTANA CLDN18 (43-14A) RxDx Assay helps fulfil an unmet medical need by enabling clinicians…

Continue Reading
FDA Approves First-in-Class Drug for Gastric Cancer

FDA Approves First-in-Class Drug for Gastric Cancer

The FDA has approved Vyloy (zolbetuximab-clzb) as a first-line treatment of adults with locally advanced unresectable…

Continue Reading
Teleflex Announces Publication of a Propensity Matching

Teleflex Announces Publication of a Propensity Matching

Retrospective data from the largest comparative case series of patients undergoing laparoscopic sleeve gastrectomy (LSG) with…

Continue Reading
RNT Health Insights’ gastric cancer tool gets breakthrough device designation

RNT Health Insights’ gastric cancer tool gets breakthrough device designation

RNT Health Insights’ early gastric cancer detection tool has a 96% accuracy rate. Credit: SofikoS /…

Continue Reading
Zolbetuximab Approved to Treat Adults with Stomach or Gastro-oesophageal Junction Cancer

Zolbetuximab Approved to Treat Adults with Stomach or Gastro-oesophageal Junction Cancer

A new targeted cancer treatment, given in combination with a standard chemotherapy, for adults with stomach…

Continue Reading
Astellas’ Vyloy combination approved by MHRA as first-line gastric cancer treatment

Astellas’ Vyloy combination approved by MHRA as first-line gastric cancer treatment

Astellas Pharma’s Vyloy (zolbetuximab) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA)…

Continue Reading